Ullah Fauzia, Markouli Mariam, Orland Mark, Ogbue Olisaemeka, Dima Danai, Omar Najiullah, Mustafa Ali Moaath K
Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44915, USA.
Department of Internal Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA 02118, USA.
Cancers (Basel). 2024 Mar 27;16(7):1307. doi: 10.3390/cancers16071307.
Large granular lymphocytic (LGL) leukemia is a lymphoproliferative disorder characterized by persistent clonal expansion of mature T- or natural killer cells in the blood via chronic antigenic stimulation. LGL leukemia is associated with specific immunophenotypic and molecular features, particularly and mutations and activation of the , Fas/Fas-L and signaling pathways. Disease-related deaths are mainly due to recurrent infections linked to severe neutropenia. The current treatment is based on immunosuppressive therapies, which frequently produce unsatisfactory long-term responses, and for this reason, personalized approaches and targeted therapies are needed. Here, we discuss molecular pathogenesis, clinical presentation, associated autoimmune disorders, and the available treatment options, including emerging therapies.
大颗粒淋巴细胞(LGL)白血病是一种淋巴增殖性疾病,其特征是成熟T细胞或自然杀伤细胞通过慢性抗原刺激在血液中持续克隆性扩增。LGL白血病与特定的免疫表型和分子特征相关,特别是 以及 突变和 、Fas/Fas-L和 信号通路的激活。与疾病相关的死亡主要归因于与严重中性粒细胞减少相关的反复感染。目前的治疗基于免疫抑制疗法,其长期疗效往往不尽人意,因此需要个性化治疗方法和靶向治疗。在此,我们讨论分子发病机制、临床表现、相关自身免疫性疾病以及可用的治疗选择,包括新兴疗法。